Fycompa: payments to doctors
Payments that named Fycompa as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.7M
- Providers
- 7,697
- Transactions
- 57,132
- Average per transaction
- $100
The per-transaction average — $100 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,697 providers the average total is $740, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Eisai Inc. | $4,633,839 | 81.3% |
| Catalyst Pharmaceuticals, Inc. | $1,002,590 | 17.6% |
| Eisai Co., Ltd. | $53,868 | 0.9% |
| Hikma Pharmaceuticals USA | $4,000 | 0.1% |
| Eisai CO., LTD. | $2,069 | 0.0% |